Stay updated on Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial
Sign up to get notified when there's something new on the Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial page.

Latest updates to the Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial page
- Check4 days agoChange DetectedThe page now displays the revision label as v3.5.4, replacing the previous v3.5.3. This change signals a newer release of the site’s components and may reflect updates to the underlying platform used by the page.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page’s footer software/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3.”SummaryDifference0.0%

- Check33 days agoChange DetectedRevision: v3.5.2 supersedes v3.5.0 on the page.SummaryDifference0.0%

- Check48 days agoChange DetectedIgA glomerulonephritis was added as a listed condition, aligning with IgA nephropathy. This text update does not modify study design, eligibility criteria, or measured outcomes.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.0%

- Check69 days agoChange DetectedPage revision history updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial page.